-
Larotrectinib, sold
under the
brand name Vitrakvi, is a
medication for the
treatment of cancer. It is an
inhibitor of
tropomyosin kinase receptors TrkA...
- MEK1/2
inhibitor -
Approved 2020,
licensed by
Astrazeneca VITRAKVI (
Larotrectinib) - TRK
Inhibitor -
Approved 2018,
licensed by Loxo
Oncology (Eli Lilly)...
-
drugs that have been
approved for
medical use
include Pembrolizumab,
Larotrectinib, Selpercatinib, Entrectinib, and Pralsetinib.
Pembrolizumab was approved...
-
Altiratinib AZD-6918 CE-245677 CH-7057288 DS-6051
Entrectinib GZ-389988 K252a
Larotrectinib Lestaurtinib Milciclib ONO-4474 ONO-5390556 PLX-7486
Rebastinib SNA-120...
- L01EX09
Nintedanib L01EX10
Midostaurin L01EX11
Quizartinib L01EX12
Larotrectinib L01EX13
Gilteritinib L01EX14
Entrectinib L01EX15
Pexidartinib L01EX17...
-
Altiratinib AZD-6918 CE-245677 CH-7057288 DS-6051
Entrectinib GZ-389988 K252a
Larotrectinib Lestaurtinib Milciclib ONO-4474 ONO-5390556 PLX-7486
Rebastinib SNA-120...
- and NTRK3 genes) that is
currently in
phase 2
clinical testing. ""
Larotrectinib"" is an
inhibitor to all of the Trk
receptors (TrkA, TrkB, and TrkC)...
- offerings. The deal gave
Lilly Loxo's oral TRK inhibitor,
Vitrakvi (
Larotrectinib), LOXO-292, an oral proto-oncogene
receptor tyrosine kinase rearranged...
- ETV6-TRK3 protein, with
larotrectinib, a non-selective
inhibitor of NTRK1, NTRK2, and NTRK3
tyrosine kinases.
Larotrectinib was
approved by the FDA on...
-
Altiratinib AZD-6918 CE-245677 CH-7057288 DS-6051
Entrectinib GZ-389988 K252a
Larotrectinib Lestaurtinib Milciclib ONO-4474 ONO-5390556 PLX-7486
Rebastinib SNA-120...
